Polyrizon Ltd., a development-stage biotech company, has successfully closed a private placement transaction raising approximately $17 million. The funding will support the company's ongoing research and development of innovative intranasal hydrogel technologies.
The private placement, facilitated by Aegis Capital Corp., involved the sale of ordinary shares and investor warrants at $0.48 per unit. Polyrizon intends to use the net proceeds, combined with existing cash reserves, for general corporate purposes and working capital.
The company's proprietary Capture and Contain (C&C) hydrogel technology represents a potential breakthrough in nasal protection. The technology creates a thin hydrogel-based shield in the nasal cavity, potentially offering a barrier against viruses and allergens by preventing contact with nasal epithelial tissue.
Beyond its protective capabilities, Polyrizon is also developing advanced applications for its hydrogel technology. The company is exploring enhanced bioadhesion and prolonged retention methods for intranasal drug delivery through its Trap and Target (T&T) technology platform.
This funding signals significant potential for Polyrizon's innovative approach to nasal health and pharmaceutical delivery, positioning the company to advance its research and develop potentially transformative medical technologies.
